# US 2022/0276264 A1 · DARPin REAGENTS THAT DISTINGUISH ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE SAMPLES

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0276264 A1
- Document ID: US20220276264A1
- Status: Published application
- Kind: A1
- Application number: 17/687,587
- Filed: 2022-03-04
- Published: 2022-09-01
- Earliest claimed: 2019-01-29
- Assignees: Arizona Board of Regents on behalf of Arizona State University
- Applicants: Arizona Board of Regents On Behalf of Arizona State University
- Inventors: Michael Sierks; Stephanie Williams
- Web page: https://patentgrep.com/patent/US20220276264A1

## CPC

- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- C07K 14/4711: {Alzheimer's disease; Amyloid plaque core protein}
- C07K 2318/00: Antibody mimetics or scaffolds
- G01N 2800/2821: Alzheimer
- G01N 2800/2835: Movement disorders, e.g. Parkinson, Huntington, Tourette
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Disclosed are diagnostics kits and compositions for neurodegenerative diseases, and in particular to design ankyrin repeat protein (DARPins) reagents that distinguish Alzheimer's disease (AD) from Parkinson's disease (PD). Methods of diagnosing, monitoring treatment efficacy and developing treatments for neurodegenerative diseases, such as AD and PD are disclosed based upon the use of the AD or PD specific DARPins.

## Claims

### Claim 1

A kit for detecting a neurodegenerative disease or monitoring the efficacy of a neurodegenerative treatment, comprising at least one molecule capable of detecting at least one neurodegenerative-associated design ankyrin repeat protein (DARPin) and directions for using the kit.

### Claim 2 (depends on 1)

The kit of claim 1, further comprising at least one neurodegenerative-associated DARPin.

### Claim 3 (depends on 2)

The kit of claim 2, wherein the at least one neurodegenerative-associated DARPin is specific for detecting Alzheimer's Disease (AD) and/or Parkinson's Disease (PD).

### Claim 4 (depends on 3)

The kit of claim 3, wherein the at least one DARPin specific for detecting AD is selected from at least one member of the group consisting of: ADC1 (SEQ ID NO: 5), ADC3 (SEQ ID NO: 7), ADC6 (SEQ ID NO: 9), ADC7 (SEQ ID NO: 11).

### Claim 5 (depends on 3)

The kit of claim 3, wherein the at least one DARPin specific for detecting PD is selected from at least one member of the group consisting of: PDA6 (SEQ ID NO: 13), PDA8 (SEQ ID NO: 15), PDA9 (SEQ ID NO: 17), and PDC1 (SEQ ID NO: 19).

### Claim 6 (depends on 2)

The kit of claim 2, further comprising:
at least one positive control; and
at least one negative control.

### Claim 7

A kit for detecting a neurodegenerative disease or monitoring the efficacy of a neurodegenerative treatment, the kit comprising at least one neurodegenerative-associated design ankyrin repeat protein (DARPin).

### Claim 8 (depends on 7)

The kit of claim 7, wherein the at least one neurodegenerative-associated DARPin is specific for detecting Alzheimer's Disease (AD) and/or Parkinson's Disease (PD).

### Claim 9 (depends on 8)

The kit of claim 8, wherein the at least one DARPin specific for detecting AD is selected from at least one member of the group consisting of: ADC1 (SEQ ID NO: 5), ADC3 (SEQ ID NO: 7), ADC6 (SEQ ID NO: 9), ADC7 (SEQ ID NO: 11).

### Claim 10 (depends on 8)

The kit of claim 8, wherein the at least one DARPin specific for detecting PD is selected from at least one member of the group consisting of: PDA6 (SEQ ID NO: 13), PDA8 (SEQ ID NO: 15), PDA9 (SEQ ID NO: 17), and PDC1 (SEQ ID NO: 19).

### Claim 11 (depends on 7)

The kit of claim 7, further comprising:
at least one positive control;
at least one negative control; and
at least one antibody capable of binding to the at least one neurodegenerative-associated DARPin.

### Claim 12 (depends on 7)

The kit of claim 7, wherein the kit in an ELISA kit.

### Claim 13 (depends on 11)

The kit of claim 11, wherein the at least one antibody capable of binding to the at least one neurodegenerative-associated DARPin is a monoclonal antibody.

### Claim 14 (depends on 13)

The kit of claim 13, wherein the monoclonal antibody has an affinity of the DARPin of 0.5 μM.

### Claim 15 (depends on 11)

The kit of claim 11, further comprising a sample capture device, wherein the sample capture device contains the at least one neurodegenerative-associated DARPin, the at least one positive control, the at least one negative control, and the at least one antibody capable of binding to the at least one neurodegenerative-associated DARPin.

### Claim 16

A composition comprising at least one neurodegenerative-associated design ankyrin repeat protein (DARPin) specific for detecting Alzheimer's Disease (AD) and/or Parkinson's Disease (PD).

### Claim 17 (depends on 16)

The composition of claim 16, wherein the at least one DARPin specific for detecting AD is selected from at least one member of the group consisting of: ADC1 (SEQ ID NO: 5), ADC3 (SEQ ID NO: 7), ADC6 (SEQ ID NO: 9), ADC7 (SEQ ID NO: 11).

### Claim 18 (depends on 16)

The composition of claim 16, wherein the at least one DARPin specific for detecting PD is selected from at least one member of the group consisting of: PDA6 (SEQ ID NO: 13), PDA8 (SEQ ID NO: 15), PDA9 (SEQ ID NO: 17), and PDC1 (SEQ ID NO: 19).

### Claim 19 (depends on 16)

The composition of claim 16, further comprising at least one antibody capable of binding to the at least one neurodegenerative-associated DARPin.

### Claim 20 (depends on 19)

The composition of claim 19, further comprising
at least one positive control; and
at least one negative control.
